Non-GLP-1 evidence-based weight and metabolic treatments There are other ways to help with weight loss and weight management besides using GLP-1 medicines
Obesity Phase 2 trials showed 22.8-24.2% body-weight change at 8-12mg doses over 48 weeks, comparable to bariatric surgery
At 48 weeks, the 12mg group achieved a mean body weight reduction of 24.2% (approximately 57.8 lbs)
Rather than depending on willpower alone, GLP-1 therapy works with your bodys hunger signaling
Dose escalation timing Many researchers plateau because they have not yet reached their optimal dose
The drug, which Novo Nordisk calls simply the Wegovy pill, uses the same active ingredient - semaglutide - that powers the original Wegovy, along with its sister drug for diabetes, Ozempic